INS and metabolic dysfunction-associated steatotic liver disease: Together, these effects reduce glucose and insulin levels, enhance fatty acid β-oxidation, lower insulin resistance, and promote caloric deficit, all relevant to MASLD pathophysiology [24,135,136].